{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:37:29Z","timestamp":1788957449584,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GEEM"},{"name":"Unidade Local de Sa\u00fade de S\u00e3o Jos\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Studies evaluating COVID-19 primary vaccination with two vaccines reported a blunt response in Multiple Sclerosis (MS) patients under anti-CD20 and sphingosine-1-phosphate (S1P) modulators. An extended primary vaccination (EPV) was recommended in immunosuppressed MS patients. Data on the effectiveness of the EPV and subsequent booster dose are limited. A prospective cohort study (n\u2009=\u2009270) was conducted to evaluate the humoral and cellular immunogenicity of the EPV scheme in immunocompromised MS patients (i.e., treated with anti-CD20, S1P modulators, natalizumab, teriflunomide, or dimethyl fumarate) vs. regular primary vaccination in non-treated patients - primary course (PC) cohort. The effect of a subsequent booster dose was also assessed\u00a0- first booster (FB) cohort . The seroconversion rates were 55% and 56% in anti-CD20 and 75% and 67% in S1P modulators group in PC and FB cohort,\u00a0respectively, and 100% in the remaining groups. A positive SARS-CoV-2 Spike T-spot was observed in 22% of patients under S1P modulators in PC cohort and 67% in FB cohort; the remaining groups had 75% or more. Similar rates of breakthrough infection were observed in both groups vs. controls. Compared to non-treated MS patients, immunosuppressed patients under anti-CD20 and S1P modulators drugs receiving EPV scheme or booster dose still present lower protection rates to SARS-CoV-2.<\/jats:p>","DOI":"10.1007\/s00415-025-12991-8","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:54:18Z","timestamp":1743144858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-3258","authenticated-orcid":false,"given":"Filipa","family":"Ladeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf COVACiMS collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Grine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Canto-Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Silva-Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Ramos-Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Salavisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Serrazinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"de S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arraiolos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"12991_CR1","unstructured":"COVID-19 deaths | WHO COVID-19 dashboard. https:\/\/data.who.int\/dashboards\/covid19\/deaths. Accessed 22 Nov 2024"},{"key":"12991_CR2","unstructured":"EU Vaccines Strategy. https:\/\/commission.europa.eu\/strategy-and-policy\/coronavirus-response\/public-health\/eu-vaccines-strategy_en. Accessed 9 May 2024"},{"key":"12991_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ-2021-068632","author":"LARY Bin","year":"2022","unstructured":"Bin LARY, Wong SY, Chai LYA et al (2022) Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. https:\/\/doi.org\/10.1136\/BMJ-2021-068632","journal-title":"BMJ"},{"key":"12991_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/TROPICALMED7050081\/S1","author":"S Gopinath","year":"2022","unstructured":"Gopinath S, Ishak A, Dhawan N et al (2022) Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: a systematic review. Trop Med Infect Dis. https:\/\/doi.org\/10.3390\/TROPICALMED7050081\/S1","journal-title":"Trop Med Infect Dis"},{"key":"12991_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835\/ASSET\/IMAGES\/LARGE\/10.1177_17562864211012835-FIG2.JPEG","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S et al (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864211012835\/ASSET\/IMAGES\/LARGE\/10.1177_17562864211012835-FIG2.JPEG","journal-title":"Ther Adv Neurol Disord"},{"key":"12991_CR6","doi-asserted-by":"publisher","unstructured":"EC T, N V, V A, et al (2021) COVID-19 vaccine response in people with multiple sclerosis. https:\/\/doi.org\/10.1101\/2021.07.31.21261326","DOI":"10.1101\/2021.07.31.21261326"},{"key":"12991_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2021.103581","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Schiavetti I, Carmisciano L et al (2021) Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease-modifying therapies. EBioMedicine. https:\/\/doi.org\/10.1016\/J.EBIOM.2021.103581","journal-title":"EBioMedicine"},{"key":"12991_CR8","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/S41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM et al (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27:1990\u20132001. https:\/\/doi.org\/10.1038\/S41591-021-01507-2","journal-title":"Nat Med"},{"key":"12991_CR9","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/JAMANEUROL.2021.3599","volume":"78","author":"L Brill","year":"2021","unstructured":"Brill L, Rechtman A, Zveik O et al (2021) Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 78:1510\u20131514. https:\/\/doi.org\/10.1001\/JAMANEUROL.2021.3599","journal-title":"JAMA Neurol"},{"key":"12991_CR10","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1177\/13524585221102918","volume":"28","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I, Cordioli C, Stromillo ML et al (2022) Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler 28:2106\u20132111. https:\/\/doi.org\/10.1177\/13524585221102918","journal-title":"Mult Scler"},{"key":"12991_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2022.104042","author":"MP Sormani","year":"2022","unstructured":"Sormani MP, Schiavetti I, Inglese M et al (2022) Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease-modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine. https:\/\/doi.org\/10.1016\/J.EBIOM.2022.104042","journal-title":"EBioMedicine"},{"key":"12991_CR12","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3631244","author":"MP Sormani","year":"2020","unstructured":"Sormani MP, De Rossi N, Schiavetti I et al (2020) Disease modifying therapies and covid-19 severity in multiple sclerosis. SSRN Electron J. https:\/\/doi.org\/10.2139\/ssrn.3631244","journal-title":"SSRN Electron J"},{"key":"12991_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.156978","author":"JJ Sabatino","year":"2022","unstructured":"Sabatino JJ, Mittl K, Rowles WM et al (2022) Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine\u2013induced antibody and T-cell immunity and function. JCI Insight. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.156978","journal-title":"JCI Insight"},{"key":"12991_CR14","unstructured":"Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals | FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised. Accessed 13 May 2024"},{"key":"12991_CR15","unstructured":"COVID-19: DGS recomenda dose adicional da vacina para imunossuprimidos - ePortugal.gov.pt. https:\/\/eportugal.gov.pt\/noticias\/covid-19-dgs-recomenda-dose-adicional-da-vacina-para-imunossuprimidos. Accessed 13 May 2024"},{"key":"12991_CR16","unstructured":"(2021) Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons Interim guidance"},{"key":"12991_CR17","unstructured":"Grupo de Estudos de Esclerose M\u00faltipla (2021) Informa\u00e7\u00e3o do Grupo de Estudos de Esclerose M\u00faltipla sobre 3a dose da vacina contra a COVID-19. https:\/\/www.spneurologia.com\/files\/pdf\/52_3-dose-de-vacina-contra-a-covid-19-informacao-do-grupo-de-es_1632330856.pdf. Accessed 27 Jun 2024"},{"key":"12991_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2114583\/SUPPL_FILE\/NEJMOA2114583_DATA-SHARING.PDF","author":"EG Levin","year":"2021","unstructured":"Levin EG, Lustig Y, Cohen C et al (2021) Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMOA2114583\/SUPPL_FILE\/NEJMOA2114583_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"12991_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/J.EJIM.2021.10.027","volume":"94","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S et al (2021) Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: the need for a booster vaccine dose? Eur J Intern Med 94:105\u2013107. https:\/\/doi.org\/10.1016\/J.EJIM.2021.10.027","journal-title":"Eur J Intern Med"},{"key":"12991_CR20","unstructured":"Vaccine History Timeline | Immunize.org. https:\/\/www.immunize.org\/vaccines\/vaccine-timeline\/. Accessed 27 Jun 2024"},{"key":"12991_CR21","unstructured":"Truong et al. Persistent SARS-CoV-2 Infection and Increasing Viral Variants in Children and Young Adults With Impaired Humoral Immunity. medRxiv 2021. - Pesquisa Google. https:\/\/www.google.com\/search?client=safari&rls=en&q=Truong+et+al.+Persistent+SARS-CoV-2+Infection+and+Increasing+Viral+Variants+in+Children+and+Young+Adults+With+Impaired+Humoral+Immunity.+medRxiv+2021.&ie=UTF-8&oe=UTF-8. Accessed 13 May 2024"},{"key":"12991_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/INFDIS\/JIAA666","volume":"223","author":"JH Baang","year":"2021","unstructured":"Baang JH, Smith C, Mirabelli C et al (2021) Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis 223:23\u201327. https:\/\/doi.org\/10.1093\/INFDIS\/JIAA666","journal-title":"J Infect Dis"},{"key":"12991_CR23","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMC2031364\/SUPPL_FILE\/NEJMC2031364_DISCLOSURES.PDF","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J et al (2020) Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med 383:2291\u20132293. https:\/\/doi.org\/10.1056\/NEJMC2031364\/SUPPL_FILE\/NEJMC2031364_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"12991_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.10.20248871","author":"E Khatamzas","year":"2021","unstructured":"Khatamzas E, Rehn A, Muenchhoff M et al (2021) Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. MedRxiv. https:\/\/doi.org\/10.1101\/2021.01.10.20248871","journal-title":"MedRxiv"},{"key":"12991_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/J.JIAC.2020.12.001","volume":"27","author":"Y Nakajima","year":"2021","unstructured":"Nakajima Y, Ogai A, Furukawa K et al (2021) Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother 27:387\u2013389. https:\/\/doi.org\/10.1016\/J.JIAC.2020.12.001","journal-title":"J Infect Chemother"},{"key":"12991_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2020.10.049","author":"VA Avanzato","year":"2020","unstructured":"Avanzato VA, Matson MJ, Seifert SN et al (2020) Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. https:\/\/doi.org\/10.1016\/J.CELL.2020.10.049","journal-title":"Cell"},{"key":"12991_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature. https:\/\/doi.org\/10.1038\/s41586-020-2521-4","journal-title":"Nature"},{"key":"12991_CR28","doi-asserted-by":"publisher","unstructured":"ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs - Susana Otero-Romero, Christine Lebrun-Fr\u00e9nay, Sa\u00fal Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintor\u00e9, 2023. https:\/\/journals.sagepub.com\/doi\/full\/https:\/\/doi.org\/10.1177\/13524585231168043?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org. Accessed 27 Jan 2025","DOI":"10.1177\/13524585231168043?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org"},{"key":"12991_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2022.104102","author":"X Wu","year":"2022","unstructured":"Wu X, Wang L, Shen L, Tang K (2022) Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. https:\/\/doi.org\/10.1016\/J.EBIOM.2022.104102","journal-title":"EBioMedicine"},{"key":"12991_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/JNNP-2022-329123","volume":"93","author":"M Etemadifar","year":"2022","unstructured":"Etemadifar M, Nouri H, Pitzalis M et al (2022) Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. J Neurol Neurosurg Psychiatry 93:986\u2013994. https:\/\/doi.org\/10.1136\/JNNP-2022-329123","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12991_CR31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/13524585221134216","volume":"29","author":"AT Reder","year":"2023","unstructured":"Reder AT, Stuve O, Tankou SK, Leist TP (2023) T-cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Mult Scler 29:648\u2013656. https:\/\/doi.org\/10.1177\/13524585221134216","journal-title":"Mult Scler"},{"key":"12991_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/JAMANEUROL.2021.5109","volume":"79","author":"M K\u00f6nig","year":"2022","unstructured":"K\u00f6nig M, Torgauten HM, Tran TT et al (2022) Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 Vaccination. JAMA Neurol 79:307\u2013309. https:\/\/doi.org\/10.1001\/JAMANEUROL.2021.5109","journal-title":"JAMA Neurol"},{"key":"12991_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/JNNP-2022-330175","volume":"94","author":"A Aiello","year":"2023","unstructured":"Aiello A, Coppola A, Ruggieri S et al (2023) Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. J Neurol Neurosurg Psychiatry 94:290\u2013299. https:\/\/doi.org\/10.1136\/JNNP-2022-330175","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12991_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2022.103937","author":"EC Tallantyre","year":"2022","unstructured":"Tallantyre EC, Scurr MJ, Vickaryous N et al (2022) Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/J.MSARD.2022.103937","journal-title":"Mult Scler Relat Disord"},{"key":"12991_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31142-5","author":"KJ Kramer","year":"2022","unstructured":"Kramer KJ, Wilfong EM, Voss K et al (2022) Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-31142-5","journal-title":"Nat Commun"},{"key":"12991_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104411","author":"M Schraad","year":"2023","unstructured":"Schraad M, Uphaus T, Runkel S et al (2023) Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104411","journal-title":"EBioMedicine"}],"updated-by":[{"DOI":"10.1007\/s00415-025-13494-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12991-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:25:39Z","timestamp":1763468739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12991-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["12991"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12991-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Misspelling in the existing author's name in the acknowledgement sections have been updated","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-025-13494-2","URL":"https:\/\/doi.org\/10.1007\/s00415-025-13494-2","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filipa Ladeira has received a consultant and speaking fees from Novartis, Roche, Sanofi Genzyme, Biogen and Merck, as well as research support from Biogen, Roche and support for scientific meetings from Novartis, Biogen, Sanofi Genzyme, and Teva. Claudia N\u00f3brega has no conflict of interest to declare. Jo\u00e3o Cerqueira has received consultancy fees from Biogen, Roche, Novartis, Almirall, Janssen, Bristol-Myers-Squibb, Merck, and Zambon; and research grants from Biogen, Roche, Merck, and Novartis, as well as the Portuguese Foundation for Science and Technology and Clinical Academic Centre Braga. Carlos Capela has received honoraria for participating on advisory boards from Biogen, Janssen, Merck, Novartis, Roche, and Sanofi; and participating in conferences sponsored by Almirall, Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi. Additionally, received travel expenses compensations for participating in scientific meetings from Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva. Cristina Ara\u00fajo has received speaker fees from Biogen, Merck, Sanofi- Genzyme, Roche, and Novartis, participated on advisory board for Merck, Novartis, and Biogen, and received travel funding from Biogen, Merck, and Sanofi-Genzyme. Jo\u00e3o Sequeira has received personal compensation for participation in advisory boards from Janssen, Merck, Novartis, Roche, and Sanofi; consulting fees from Novartis; speaking honoraria from Almirall, Merck, Novartis, Roche and Sanofi; and travel expenses for scientific meetings from Bayer, Biogen, Janssen, Merck, Novartis, Sanofi, and Teva. Marisa Brum has received a consultant and speaking fees from Biogen Idec and Merck, as well a scientific meetings support from Novartis, Roche, Biogen Idec, Merck, Bayer, Sanofi Genzyme, and Teva, and has received honoraria for participating on advisory boards from Biogen and Merck. Stephanie Castro has no conflict of interest to declare. Teresa Grine has no conflict of interest to declare. Jo\u00e3o Canto-Gomes has no conflict of interest to declare. Sara Silva-Ferreira has no conflict of interest to declare. Catarina Ramos-Fernandes has no conflict of interest to declare. Irene Mendes has no conflict of interest to declare. Dina Silva has no conflict of interest to declare. Manuel Salavisa has received support for scientific meetings from Sanofi Genzyme, Roche, and Merck Serono, and has received additional personal compensation for participating on advisory boards and serving as a speaker in meetings sponsored by Roche, Merck Serono. Filipa Serrazina has received support for scientific meetings from Novartis, Roche, Sanofi Genzyme, Biogen, and Merck, and has received additional personal compensation for participating as a speaker in meetings sponsored by Novartis and Merck. Jo\u00e3o de S\u00e1 has received consultancy gees from Roche and Merck. Jo\u00e3o Ferreira has no conflict of interest to declare. Miguel Leal Rato has received support for scientific meetings, courses, and speaker fees from Bristol-Myers Squibb, Merck, Novartis, Roche, and Sanofi. Miguel Sch\u00f6n has no conflict of interest to declare. Joana Guimar\u00e3es has received a consultant and speaking fees from Novartis, Roche, Sanofi Genzyme, Biogen Idec, and Merck, as well as research support from Biogen Idec, and Roche and support for scientific meetings from Novartis, Biogen Idec, Sanofi Genzyme, and Teva. Teresa Mendon\u00e7a has no conflict of interest to declare. Pedro Abreu has received a consultancy and speaking fees from Biogen, Novartis, Merck Serono, Roche, and Sanofi, and support for scientific meetings from Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva. Maria Jos\u00e9 S\u00e1 has no conflict of interest to declare. Rui Guerreiro has received honoraria for participating as speaker and consultant on advisory boards from Biogen Idec, Merck, Novartis, and Sanofi-Genzyme and has received financial support for scientific meetings from Biogen Idec, Janssen, Merck, Novartis, and Roche. Ana Arraiolos has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"288"}}